Table 3 A, B Summary of binding affinity between RBDs and therapeutic mAbs (A) casirivimab+imdevimab, (B) sotrovimab

From: Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy

A

 

Casirivimab

Casirivimab

Imdevimab

Imdevimab

RBD

KD(nM)

Fold reduction

KD(nM)

Fold reduction

Delta RBD WT

0.36

-

9.4

-

Delta RBD + E406D

7.1

20

15

1.6

Delta RBD + E406Q

14

38

8.9

1.1*

Delta RBD + G4465

0.56

1.6

734

78

Delta RBD + G446V

0.64

1.8

Very weak binding

Very weak binding

Delta RBD + Y453F

67

186

9.8

1.0

Delta RBD + L455F

44

122

11

1.2

Delta RBD + L4555

133

369

9.1

1.0

Delta RBD + G446V + Y453F

125

347

Very weak binding

Very weak binding

Delta RBD + G446V + L455F

69

192

Very weak binding

Very weak binding

B

 

Sotrovimab

Sotrovimab

RBD

KD(nM)

Fold reduction

BA.1 RBD WT

0.17

-

BA. 1 RBD + P337R

753

4428

BA. 1 RBD + P337S

332

1951

BA. 1 RBD + E340A

3415

20088

BA. 1 RBD + E340D

764

4494

BA. 1 RBD + E34OK

3441

20241

BA. 1 RBD + E340V

345

2027

  1. The fold reduction in affinity between RBD mutants and wild-type RBD is calculated. The number labelled with a star indicates a fold increase in affinity. See also Figs. S2 and 3.
Back to article page